Evidence map›Paper›PMID 40268898›Full record

ArticleBlood cancer journal2025

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.

Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi, Anannya Patwari, Metodi Balev, Divaya Bhutani, Asis Shrestha, Sharmilan Thanendrarajan and 13 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Meera MohanDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. memohan@mcw.edu.ORCID http://orcid.org/0000-0002-6913-6526
Aniko SzaboDivision of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0002-8129-0614
Heloise CheruvalathMedical College of Wisconsin Medical School, Milwaukee, WI, USA.
Anna ClennonHematology Oncology, Aurora St. Luke's Medical Center, Milwaukee, WI, USA.
Vineel BhatlapenumarthiDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Anannya PatwariDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Metodi BalevMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Divaya BhutaniMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Asis ShresthaMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Sharmilan ThanendrarajanMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Binod DhakalDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0002-4377-9742
Maurizio ZangariMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Anup TrikannadMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Sruthi VellankiMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.
Samer Al-HadidiMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.ORCID http://orcid.org/0000-0003-4297-8042
Suzanne LentzschMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Frits van RheeMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.ORCID http://orcid.org/0000-0001-9959-1282
Aishee BagDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0001-9148-2380
Anita D'SouzaDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0002-1092-5643
Nishi ShahDivision of Hematological Malignancies, Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-4723-6745
Rajshekhar ChakrabortyMultiple Myeloma and Amyloidosis Program, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7336-3003
Mansi R ShahDivision of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Carolina SchinkeMyeloma Center, University of Arkansas for Medical Science, Little Rock, AR, USA.ORCID http://orcid.org/0000-0002-2699-1741

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main objective of this multi-institutional study is to understand the effect of primary intravenous immunoglobulin (IVIG) replacement on clinical outcomes in recipients of BCMA-directed bispecific antibody (bsAb), where infection remains an important cause of morbidity and mortality. This is a retrospective study of patients treated with either standard of care teclistamab or BCMA-directed investigational bsAb between Nov 2017 and Dec 2023. Primary IVIG prophylaxis was defined as starting IVIG prior to first documented infection. All analyses were adjusted for immortal-time bias inherent in this grouping. A total of 225 patients were included in this analysis. Primary IVIG prophylaxis was defined as starting IVIG prior to first documented infection. The median follow-up of patients treated with and without primary IVIG prophylaxis was, 9 and 11 months, respectively. The cumulative incidence of all grade infections at 12 months with and without primary IVIG prophylaxis were 56% (95%CI 40%,78%) and 60% (95% CI 48%, 76%); p = 0.72, respectively. The 12-month cumulative incidence of ≥ grade 3 infections was 35% (95% CI 21%, 57%) with primary IVIG prophylaxis and 45% (95% CI 34%, 60%) without; p = 0.37. The median infection free survival (IFS) for all-grade infections was 7.7 (95% CI 3.3, 14) months with primary IVIG prophylaxis and 3 (95% CI 2.6, 4.5) months without (p = 0.021). The median ≥ grade 3 IFS was 14 (95% CI 8.8, NR) and 7.5 (95% CI 6.1, 14) months, with and without primary IVIG respectively; p = 0.022. Patients on primary IVIG prophylaxis had a superior progression-free-survival (PFS) [median PFS 15 vs 8 months; p = 0.026] and overall-survival (OS) [median OS 16 vs 44 months; p = 0.007]. On multivariate analysis, primary IVIG prophylaxis was independently associated with improved OS (HR = 0.37; p = 0.021), while the presence of extra-medullary (HR = 2.71; p = <0.001) and high-risk disease (HR = 1.88; p = 0.031) conferred poor outcomes. In recipients of BCMA-directed bsAb, IVIG supplementation was associated with an improved clinical outcome, including favorable IFS and OS.

Indexed as

Antibodies, BispecificB-Cell Maturation AntigenImmunoglobulins, IntravenousInfectionsMultiple MyelomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesAntibodies, BispecificB-Cell Maturation AntigenImmunoglobulins, Intravenous

Identifiers

PMID40268898
PMCPMC12018942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.